Get started
Author

Natalie Grover

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
2025 · Michael Wang, Michael Wang, et al. · Journal of Clinical Oncology · 67
339 | Outcomes in an International Multicentre Study of 600 Patients With Cns Relapse of Large B Cell Lymphoma: Compartment of Relapse Is Prognostic
2025 · D. Baggio, S. Han, et al. · Hematological Oncology · 1
PDF
When too late is too late: timing of CAR T-cell therapy in SLE & lupus nephritis
2026 · Saira Sheikh, Shaun Jackson, et al. · Frontiers in Immunology
PDF
Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
2026 · Daniel K. Reef, Natalie Grover · AME Clinical Trials Review
Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real‐world analysis from 20 US centers
2026 · Allison M. Bock, Peirong Hao, et al. · HemaSphere
Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults
2026 · Saullo, Jennifer, Grover, Natalie, et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill)
Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy
2021 · Voorhees, T.J., Ghosh, N., et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill)
Works count: 7
Citation count: 67
H-index: 1
I10-index: 1
Year
Topic
Type